139 results
6-K
EX-1
BLRX
Bioline Rx Ltd
30 May 24
BioLineRx Announces Clinical Trial Agreement with St. Jude Children’s Research Hospital, Inc. to
7:16am
of stem cells using the mobilization agent plerixafor is the current strategy to collect HSCs for SCD gene therapies, however limitations exist including
6-K
EX-99.3
BLRX
Bioline Rx Ltd
28 May 24
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate
7:11am
, we have an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions.
We seek to develop and commercialize a pipeline … success. Our strategy includes commercializing our therapeutic candidates by way of out-licensing arrangements with biotechnology and pharmaceutical
424B5
BLRX
Bioline Rx Ltd
1 Apr 24
Prospectus supplement for primary offering
10:30am
of motixafortide for patients with sickle cell disease and pancreatic cancer. In addition, we have an off-strategy, legacy therapeutic product called BL-5010 … candidates that we believe exhibit a high probability of therapeutic and commercial success. Our strategy includes commercializing our therapeutic
20-F/A
2023 FY
BLRX
Bioline Rx Ltd
26 Mar 24
Annual report (foreign) (amended)
4:57pm
or significant changes in a licensee’s business strategy may adversely affect the licensee’s willingness or ability to complete its obligations under any … to terminate the Agalimmune Development Agreement effective March 15, 2024.
An important element of our strategy is maintaining relationships
F-3
t1ydgw7efre9tw5sayb
29 Dec 23
Shelf registration (foreign)
4:15pm
6-K
EX-99
2ozihvz2pbaov0xy
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
glft 7dy0zx
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
k2itoy
30 Aug 23
Current report (foreign)
6:45am
6-K
EX-99
s9dlx bgew
23 Jun 23
Notice of Annual General Meeting of Shareholders
4:16pm
6-K
EX-99
0sc w3v9z3fn
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
8v6hkaojqrrug8nxece
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am
6-K
EX-99
yufz8eu
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am
6-K
EX-99
1c6d3o26d34 nze
27 Sep 22
BioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilization
7:00am
424B5
qe0h 5l9b
20 Sep 22
Prospectus supplement for primary offering
4:30pm
6-K
EX-99
nvoxxa8db090 gi
16 Aug 22
BioLineRx Reports Second Quarter 2022 Financial Results
7:19am
6-K
EX-99
52kuly 1lp1ge
16 Aug 22
BioLineRx Reports Second Quarter 2022 Financial Results
7:19am
6-K
EX-99
wyn c707vil
16 Jun 22
BioLineRx Announces Appointment of Commercial Strategy
7:05am
6-K
EX-99
wtv56kjlil7i62bbo
27 May 22
2022 Annual General Meeting of Shareholders
4:30pm
6-K
EX-99
e23gs0n814g bgvaoiu
11 May 22
BioLineRx Reports First Quarter 2022 Financial Results
7:14am